ITLN1 and neoplasm: In malignancies where omentin-1 demonstrates tumor-suppressive activity—such as gastric cancer, hepatocellular carcinoma, and specific subtypes of colorectal cancer—direct therapeutic approaches using recombinant omentin-1 or newly developed omentin-mimetic compounds should be evaluated in preclinical models.